MJ

Mohd Jameel

Active Director Director DIN 06689551
DIN 06689551 First appointment Oct 2013 Primary industry Pharma
Unlock full profile Investments · shareholding · contact details
Current companies 1 active board seats
Total affiliations 1 Since Oct 2013
Shareholding value •••• Premium profile

About Mohd Jameel

Data last updated:

Mohd Jameel is a Director at Hoffen Remedies Private Limited (since 2013). The company operates in Pharma. Hoffen Remedies Private Limited reported revenue of ₹39,229 (FY 2024).

DIN 06689551
Primary Designation Director
Industry Pharma
First Appointment 17 Oct 2013
Oldest Company Age 13 yrs
Largest company Hoffen Remedies Private Limited · ₹39,229 (FY 2024)

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Hoffen Remedies Private Limited U24297UP2013PTC060137
Director17 Oct 20132013₹39,229 (FY 2024)Active

Board colleagues of Mohd Jameel

NameDINCompanyDesignation
Mohammad Asif06689547Hoffen Remedies Private LimitedWhole-Time Director

Directorship timeline

Open interactive timeline →
Hoffen Remedies Private Limited
Premium access

Shareholding and investment profile for Mohd Jameel

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Mohd Jameel

Mohd Jameel currently holds 1 directorship: Hoffen Remedies Private Limited (Director, since 17 Oct 2013, revenue ₹39,229 (FY 2024)).

Mohd Jameel was first appointed on 17 Oct 2013 as Director at Hoffen Remedies Private Limited.

The current boards of Mohd Jameel's companies include Mohammad Asif (Hoffen Remedies Private Limited).

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available